wbldb
home
|
authors
|
theses
Ferrari, Serge
1
Zoledronate following denosumab discontinuation: partial reassurance but no confidence
J Bone Miner Res
. July 2020;35(7):1205-1206
©2020 American Society for Bone and Mineral Research
Affiliations
1
Geneva University Hospital
and Faculty of Medicine, Geneva, Switzerland
Links
DOI:
10.1002/jbmr.4022
PubMed:
32315077
WoS:
000527017900001
History
Received: 2020-03-2
Revised: 2020-03-19
Accepted: 2020-03-31
Online: 2020-04-21
Cited Works (8)
Year
Entry
2017
Reid IR, Horne AM, Mihov B, Gamble GD. Bone loss after denosumab: only partial protection with zoledronate.
Calcif Tiss Int
. October 2017;101(4):371-374.
2017
Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwiński E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster J-Y, Roux C, Malouf J, Bradley MN, Daizadeh NS, Wang A, Dakin P, Pannacciulli N, Dempster DW, Papapoulos S. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.
Lancet Diabetes Endocrinol
. July 2017;5(7):513-523.
2020
Everts‐Graber J, Reichenbach S, Ziswiler HR, Studer U, Lehmann T. A single infusion of zoledronate in postmenopausal women following denosumab discontinuation results in partial conservation of bone mass gains.
J Bone Miner Res
. July 2020;35(7):1207-1215.
2011
Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang Y-C, Grazette L, San Martin J, Gallagher JC. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
J Clin Endocrinol Metab
. April 2011;96(4):972-980.
2018
Cummings SR, Ferrari S, Eastell R, Gilchrist N, Jensen J-EB, McClung M, Roux C, Törring O, Valter I, Wang AT, Brown JP. Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension.
J Bone Miner Res
. February 2018;33(2):190-198.
2019
Anastasilakis AD, Papapoulos SE, Polyzos SA, Appelman-Dijkstra NM, Makras P. Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment: a prospective 2-year clinical trial.
J Bone Miner Res
. December 2019;34(12):2220-2228.
2020
Tripto-Shkolnik L, Fund N, Rouach V, Chodick G, Shalev V, Goldshtein I. Fracture incidence after denosumab discontinuation: real-world data from a large healthcare provider.
Bone
. January 2020;130:115150.
2017
Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Guañabens N, Obermayer-Pietsch B, Ralston SH, Eastell R, Zillikens MC. Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS.
Bone
. December 2017;105:11-17.
Cited By (2)
Year
Entry
2021
Everts-Graber J, Reichenbach S, Gahl B, Ziswiler H, Studer U, Lehmann T. Risk factors for vertebral fractures and bone loss after denosumab discontinuation: a real-world observational study.
Bone
. March 2021;144:115830.
2022
Everts-Graber J, Reichenbach S, Gahl B, Häuselmann H, Ziswiler H-R, Studer U, Lehmann T. Effects of zoledronate on bone mineral density and bone turnover after long-term denosumab therapy: observations in a real-world setting.
Bone
. October 2022;163:116498.